Fredun Pharmaceuticals Ltd — Important, 14-02-2026: Company Update

Fredun Pharmaceuticals' Monitoring Agency reported deviations in the use of preferential allotment proceeds for the quarter. Deviations included temporarily routing Rs. 37 crore through a Cash Credit Account and classifying loan EMI payments under working capital and Capex, which were not explicitly defined. The agency also flagged discrepancies in unutilized funds and commingling of proceeds, citing a 25-50% deviation range. The company, which raised Rs. 97.78 crore from a Rs. 149.50 crore preferential issue, clarified these were operational without fund diversion. Unutilized funds total Rs. 86.64 crore.